Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway

L. J. Bugaj, A. J. Sabnis, A. Mitchell, J. E. Garbarino, J. E. Toettcher, T. G. Bivona, W. A. Lim

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

The Ras-Erk (extracellular signal-regulated kinase) pathway encodes information in its dynamics; the duration and frequency of Erk activity can specify distinct cell fates. To enable dynamic encoding, temporal information must be accurately transmitted from the plasma membrane to the nucleus. We used optogenetic profiling to show that both oncogenic B-Raf mutations and B-Raf inhibitors can cause corruption of this transmission, so that short pulses of input Ras activity are distorted into abnormally long Erk outputs. These changes can reshape downstream transcription and cell fates, resulting in improper decisions to proliferate. These findings illustrate how altered dynamic signal transmission properties, and not just constitutively increased signaling, can contribute to cell proliferation and perhaps cancer, and how optogenetic profiling can dissect mechanisms of signaling dysfunction in disease.

Original languageEnglish (US)
Article numbereaao3048
JournalScience
Volume361
Issue number6405
DOIs
StatePublished - Aug 31 2018

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway'. Together they form a unique fingerprint.

  • Cite this

    Bugaj, L. J., Sabnis, A. J., Mitchell, A., Garbarino, J. E., Toettcher, J. E., Bivona, T. G., & Lim, W. A. (2018). Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science, 361(6405), [eaao3048]. https://doi.org/10.1126/science.aao3048